The global ventricular fibrillation treatment market is slated to reach a valuation of USD 9.19 billion in 2023. According to Future Market Insights, the market is expected to grow at an 8.5% CAGR until 2033, valued at USD 20.78 billion.
The increase in the number of cardiac cases worldwide is the major factor that is driving the growth of the global ventricular fibrillation treatment market. The increasing focus on healthcare across different regions is another factor that is expected to drive the growth of the market. Additionally, the growth in medical tourism in certain developing countries will also lead to a contribution to the global ventricular fibrillation treatment market.
But it is also considered that the high cost of the technologies required in the treatment of the global ventricular fibrillation market is coupled with strict regulations that will hamper the growth of the industry.
Also, there has been a noticeable rise in the number of patients suffering from Ventricular fibrillation is disorderly and irregular electrical activity in the heart’s ventricles. The ventricles, in turn, do not contract and pump blood out of the heart into the body where VFib is an emergency. So, if VFib develops, the body will not receive the blood it needs as the heart is no longer pumping.
The only way to correct a heart that is experiencing VFib is to give it an electrical shock with a defibrillator. If the shock is administered in time, a defibrillator can revert the heart to a normal, healthy rhythm.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2023) | USD 9.19 billion |
| Projected Forecast Value (2033) | USD 20.78 billion |
| Growth rate | 8.5% CAGR |
| Forecast period | 2023 to 2033 |
Explore FMI!
Book a free demo
The global Ventricular Fibrillation Treatment Market grew at a CAGR of 6.8% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Earlier, the most common presentation for VF is sudden collapse from cardiac arrest leading to SCD. This results from improper ventricular contraction resulting in low cardiac output. Patients may demonstrate signs of acute MI such as chest pain, shortness of breath, nausea, and vomiting before the event. Patients with a known history of coronary artery disease or congestive heart failure may show a worsening of chronic symptoms such as angina, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and pedal edema. At the time of presentation, patients are unconscious, unresponsive, and have no palpable pulse. Without prompt action, this leads to death within the next few minutes. Patients with ICD for primary or secondary prevention can experience shock from ICD firing at the time of experiencing VF.
Nowadays, ICDs can reduce the risk of sudden cardiac death by the development of an entirely subcutaneous ICD (S-ICD) system with efficacy similar to that of conventional ICD in terminating VF which has been a major advance in device technology. Although randomized comparative data are not yet available, pooled data from the EFFORTLESS and IDE trials have shown the S-ICD to be a safe and effective alternative to conventional transvenous ICDs- especially in younger patients with HCM, genetic channelopathies, and adult complex congenital heart disease.
Introduction of interventional cardiology devices
The high utilization of cardiac diagnostics and monitoring devices for ventricular fibrillation treatment is boosting the sales of diagnostic devices. Some of the devices are Holter monitors, ECGs, diagnostic catheters, etc. The advent of portable and digital systems and the expanding usage of these devices in interventional medical procedures like catheter placement are thus fuelling the demand for devices required in the treatment of the ventricular fibrillation industry.
A surge in the worldwide prevalence of cardiovascular disorders
Global demand for electrophysiology devices is raising as ventricular fibrillation and other heart disorders become more common. The Centers for Disease Control and Prevention (CDC) estimate that 0.5% of the world’s population is having ventricular fibrillation where the disorder affects 2% of people under age 65, whereas it has affected about 9% of people over the age of 65 globally.
Focus on investing in R&D products
There has been a noticeable rise in the number of patients suffering from VF where the risk is noticed in patients suffering from hypertension, obesity, and other cardiovascular diseases. But this increase in the pool of patients will also significantly bring ample opportunities.
Companies are not only focusing to invest in R&D for enhancing their product, services, technology, and processes but also in creating new products where companies are also focusing on adding new features for the existence of new products for enhancing their product portfolio.
High efficiency of ablation procedures will offer several business growths
The electrophysiology market from the EP ablation catheters segment held around 48% revenue share in 2022. Among EP ablation catheters, cryoablation is majorly a growing segment that is owing to its superior therapeutic advantages. Ablation catheters deliver minimal invasive ways to efficiently treat a wide range of arrhythmias with lesser pain and blood loss.
Adoption of ventricular restoration systems
North America is expected to hold the largest market share in the ventricular fibrillation market. This is attributed to the high demand and adoption of ventricular restoration systems. This well-established healthcare system along with skilled professionals will also serve as one of the major factors leading to the dominance of this region in the global ventricular fibrillation treatment market.
Rapid advancement in the medical sector
The market in Asia-Pacific is assumed to grow at a rapid rate throughout the anticipated time. The region’s expansion is driven by a high proportion of elderly people with rising heart risk. Also, it is expected that the developing healthcare infrastructure, greater patient awareness, and higher healthcare spent in the nations such as China, India, and Japan.
Catheter ablation will have a dominant share
Catheter ablation by PDN in patients with recurrent VF or polymorphic VT in the absence of regional substrate or distinct triggers was effective in terms of reducing arrhythmia recurrence and ICD shock burden.
Catheter ablation by PDN was technically feasible with acceptable procedure durations and low complication rates.
Electrocardiograms have a dominant share
This quick and painless test measures the electrical activity of the heart. Sticky patches (electrodes) are placed on the chest and sometimes the arms and legs. Wires connect the electrodes to a computer, which displays the test results. An ECG can show if the heart is beating too fast or too slowly. In a person suffering from ventricular fibrillation, the ECG usually shows a heartbeat of about 300 to 400 beats a minute.
Atricure provides a range of products including cardiac ablation devices, left atrial appendage occlusion devices, and intraoperative testing equipment. The company went public in 2005. In Oct 2015, it acquired nContact, a privately held developer of cardiac ablation solutions.
Provider and developer of an AI-based cardiac ablation therapy software and device. It offers the product CathVision Cube which can visualize electrophysiology signals to support delivering accurate therapy. CathVision Cube is a product that comprises low-noise ablation therapy with signal quality to stream, analyze and store EP signals. The interface provides a real-time streaming review window for analysis using AI algorithms for clinical decision support. The software integrated into the device helps in analyzing and storage of EP signals.
Some of the prominent players in the global market for VF treatment are:
Some of the important developments of the key players in the market are:
In March 2021, the Rankin government announced that all public schools in Nova Scotia would be provided with automated external defibrillators. The government invested USD 700,000.
In February 2022, Medtronic said that Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters, the first and only ablation catheters licensed to treat the rising prevalence of juvenile Atrioventricular Nodal Reentrant Tachycardia, had obtained FDA extended approval (AVNRT).
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.5% from 2023 to 2033 |
| Market value in 2023 | USD 9.19 Billion |
| Market value in 2033 | USD 20.78 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Diagnostic techniques, Treatment, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Rest of Latin America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | CardioDx, Inc.; Advanced Instrumentations Inc.; Cameron Health, Inc.; Bexen Cardio; CU Medical Systems, Inc.; Biotronik SE & Co. KG; Pfizer Inc.; Heritage Pharmaceuticals Inc.; Baxter International Inc.; Lawson Health Research Institute |
| Customisation Scope | Available on Request |
The market is valued at USD 9.19 billion in 2023.
Abbott, Medtronic, and Boston Scientific Corporation are key market players.
The primary consumer for the ventricular fibrillation treatment market is the healthcare industry.
The market is estimated to reach USD 20.78 billion by 2033.
The market is forecast to register a CAGR of 8.5% throughout 2033.
Ventricular Fibrillation Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
